



1617
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231 on April 3, 2003.

Sylvia Y. Bagge
Sylvia Y. Bagge

#9
[Signature]
4/22/03

Applicant : Shoji Uchiyama, et al.
Application No. : 09/933,989
Filed : August 20, 2001
Title : USE OF AGARICUS BLAZEI MURILL TO PREVENT OR
TREAT SKIN AND OTHER DISORDERS

RECEIVED

Grp./Div. : 1617
Examiner : J. Kim
Docket No. : 47061/JWP/A596

APR 11 2003

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Post Office Box 7068
Pasadena, CA 91109-7068
April 3, 2003

Commissioner:

In response to the Restriction Requirement, please consider the following election and remarks:

REMARKS

Responsive to the requirement for restriction mailed March 25, 2003, Applicant elects, with comment, to prosecute the claims of Species II, comprising claims 31-61 and 65-69. Applicant apologizes for any confusion the previous response may have raised, however, Applicant wanted to point out that although the Examiner indicated that claims 1-30 (group I) were drawn to skin disorders and claims 31-67 (group II) were drawn to autoimmune disorders, claims 62-64 are also drawn to skin disorders not autoimmune disorders and therefore belong in group I and are not being elected by Applicant at this time.